Dianthus Therapeutics, Inc. (DNTH)
| Market Cap | 4.74B +652.8% |
| Revenue (ttm) | 1.34M -79.5% |
| Net Income | -173.66M |
| EPS | -4.17 |
| Shares Out | 54.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 560,368 |
| Open | 87.87 |
| Previous Close | 86.82 |
| Day's Range | 85.79 - 90.79 |
| 52-Week Range | 16.64 - 96.50 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 125.83 (+45.18%) |
| Earnings Date | May 5, 2026 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio... [Read more]
Financial Performance
In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $125.83, which is an increase of 45.18% from the latest price.
News
Dianthus Therapeutics to Participate in Two Investor Conferences
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to tr...
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Dianthus price target lowered to $120 from $122 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dianthus (DNTH) to $120 from $122 and keeps an Outperform rating on the shares.
Dianthus price target raised to $125 from $123 at Raymond James
Raymond James raised the firm’s price target on Dianthus (DNTH) to $125 from $123 and keeps a Strong Buy rating on the shares. Dianthus’ Q1 update highlighted pipeline progress including…
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDA...
Dianthus reports Q1 EPS (85c), consensus ($1.10)
Reports Q1 revenue $463,000, consensus $358,690. “Q1 of this year was a pivotal period for Dianthus (DNTH) as we were able to make an early GO decision in PART A…
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Dianthus Therapeutics Earnings release: Q1 2026
Dianthus Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Dianthus Therapeutics Quarterly report: Q1 2026
Dianthus Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Dianthus Therapeutics Slides: Corporate presentation
Dianthus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to tr...
Dianthus treatment of myasthenia gravis gets orphan status
Dianthus (DNTH) Therapeutics was granted FDA orphan designation for claseprubart as a treatment of myasthenia gravis, according to a post to the agency’s website.
Dianthus Therapeutics Proxy statement: Proxy filing
Dianthus Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Dianthus Therapeutics Proxy statement: Proxy filing
Dianthus Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Dianthus initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of Dianthus (DNTH) with an Outperform rating and $98 price target. The firm notes that the company’s Claseprubart is heading toward three diseases…
Dianthus Therapeutics Slides: Corporate presentation
Dianthus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Dianthus initiated with an Overweight at Wells Fargo
Wells Fargo analyst Sadia Rahman initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target The firm says the company’s claseprubart “stands out” in the complement inhibitor...
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus price target raised to $103 from $80 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Dianthus (DNTH) to $103 from $80 and keeps an Outperform rating on the shares. Following the completion of the recent…
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus price target raised to $80 from $55 at Wedbush
Wedbush raised the firm’s price target on Dianthus (DNTH) to $80 from $55 and keeps an Outperform rating on the shares. Heading into the CAPTIVATE interim readout, the firm anticipated…
Dianthus price target raised to $132 from $67 at Baird
Baird analyst Colleen Kusy raised the firm’s price target on Dianthus (DNTH) to $132 from $67 and keeps an Outperform rating on the shares. The firm’s target increase reflects its…
Dianthus upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ryan Deschner upgraded Dianthus (DNTH) to Strong Buy from Outperform with a price target of $123, up from $63. The firm is “increasingly bullish” on claseprubart following…
Dianthus price target raised to $130 from $100 at Clear Street
Clear Street analyst Bill Maughan raised the firm’s price target on Dianthus (DNTH) to $130 from $100 and keeps a Buy rating on the shares. The firm is citing the…
Dianthus announces $400M common stock offering
Dianthus (DNTH) Therapeutics announced that it has commenced an underwritten public offering of $400M of shares of its common stock or, in lieu of common stock to certain investors that…